Home › Research › Treatments
Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease
Tammie L.S. Benzinger, Arnaud Charil, Brian Andrew Gordon, Shaney E. Flores, Russ C. Hornbeck, Kristin R. Wildsmith, Sibabrata Banerjee, Guoqiao Wang et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The study includes symptomatic DIAD participants and asymptomatic mutation carriers. These groups differ in baseline amyloid levels (Symptomatic=99.86 (SD=39.45) CL; Asymptomatic=30.62 (SD=36.77) CL). Symptomatic subjects had nominally higher tau PET SUVr values across brain regions, with average values ranging from SUVR=1.94 in the hippocampus to 3.00 in the parietal cortex. Consistent with previous reports, early symptomatic DIAD subjects showed early tau accumulation in the parietal cortex, distinct from the pattern in early symptomatic sporadic AD subjects, who show initial tau accumulation in medial temporal regions (e.g., entorhinal cortex). Across the same tau PET composite ROIs, all vMRI values were nominally smaller in symptomatic vs asymptomatic subjects, reflecting atrophy. Higher atrophy in the symptomatic subjects is consistent with their higher tau PET SUVr values across all brain regions. The baseline imaging characteristics of the DIAN-TU-001 trial population reveal significant spatial differences in tau PET and vMRI between symptomatic and asymptomatic DIAD subjects. Baseline amyloid levels were consistent with the stage of disease in DIAD. Symptomatic DIAD subjects exhibit higher tau SUVR values and greater atrophy, particularly in the parietal cortex, compared to asymptomatic DIAD subjects. These tau PET findings corroborate the distinctly different pattern of tau deposition in DIAD vs. sporadic AD, as previously reported. Future analysis will elucidate the therapeutic effects of E2814 and lecanemab on this pathological tau spread.
What this study adds
Evidence grade: Low
This report describes baseline imaging in the DIAN-TU-001 Tau NexGen trial, showing that symptomatic dominantly inherited Alzheimer's participants had higher amyloid levels, higher tau PET values, and greater atrophy than asymptomatic mutation carriers. It reports only baseline characteristics and no treatment, cure, or prevention outcome.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Benzinger, T. L., Charil, A., Gordon, B. A., Flores, S. E., Hornbeck, R. C., Wildsmith, K. R., et al. (2025). Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_105301
Vancouver
Benzinger TL, Charil A, Gordon BA, Flores SE, Hornbeck RC, Wildsmith KR, et al. Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_105301. PMID: 41447186.
BibTeX
@article{benzinger2025-41447186,
author = {Benzinger, Tammie L.S. and Charil, Arnaud and Gordon, Brian Andrew and Flores, Shaney E. and Hornbeck, Russ C. and Wildsmith, Kristin R. and Banerjee, Sibabrata and Wang, Guoqiao and others},
title = {{Baseline Imaging Characteristics of Participants in the Phase II/III DIAN‐TU‐001 Tau NexGen Trial for Dominantly Inherited Alzheimer’s Disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70859_105301},
pmid = {41447186},
url = {https://doi.org/10.1002/alz70859_105301}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The study includes symptomatic DIAD participants and asymptomatic mutation carriers.
- These groups differ in baseline amyloid levels (Symptomatic=99.86 (SD=39.45) CL; Asymptomatic=30.62 (SD=36.77) CL).
- Symptomatic subjects had nominally higher tau PET SUVr values across brain regions, with average values ranging from SUVR=1.94 in the hippocampus to 3.00 in the parietal cortex.
- Consistent with previous reports, early symptomatic DIAD subjects showed early tau accumulation in the parietal cortex, distinct from the pattern in early symptomatic sporadic AD subjects, who show initial tau accumulation in medial temporal regions (e.g., entorhinal cortex).
- Across the same tau PET composite ROIs, all vMRI values were nominally smaller in symptomatic vs asymptomatic subjects, reflecting atrophy.
Why it matters
This report describes baseline imaging in the DIAN-TU-001 Tau NexGen trial, showing that symptomatic dominantly inherited Alzheimer's participants had higher amyloid levels, higher tau PET values, and greater atrophy than asymptomatic mutation carriers. It reports only baseline characteristics and no treatment, cure, or prevention outcome.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Randall John Bateman: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41447186) |
| Free to read | 2 / 2 | Free to read |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70859_105301
- PubMed: 41447186
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.